Lassa fever medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 3: Line 3:
{{CMG}}; {{AE}} {{YD}}; {{SSK}}; {{Ammu}}
{{CMG}}; {{AE}} {{YD}}; {{SSK}}; {{Ammu}}
==Overview==
==Overview==
Intravenous (IV) [[ribavirin]] is the antiviral drug of choice for the treatment of Lassa fever. Ribavirin is administered intravenously for a total of 10 days: first with a loading dose of 30 mg/kg (max. 2g) followed by a dose of 16 mg/kg (max. 1g) IV q6h for 4 days, followed by a dose of 8 mg/kg (max. 500mg) IV q8h for 6 days. In addition to antiviral therapy, management includes supportive care to adequately maintain respiratory status, as well as [[fluid]] and [[electrolyte]] balance.
Intravenous (IV) [[ribavirin]] is the antiviral drug of choice for the treatment of Lassa fever. Ribavirin is administered intravenously for a total of 10 days using the following regimen: first, loading dose of 30 mg/kg (max. 2g) followed by a dose of 16 mg/kg (max. 1g) IV q6h for 4 days, followed by a dose of 8 mg/kg (max. 500mg) IV q8h for 6 days. In addition to antiviral therapy, management includes supportive care to adequately maintain respiratory status, as well as [[fluid]] and [[electrolyte]] balance.


==Medical Therapy==
==Medical Therapy==

Revision as of 23:53, 3 January 2016

Lassa fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Lassa fever from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lassa fever medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lassa fever medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lassa fever medical therapy

CDC on Lassa fever medical therapy

Lassa fever medical therapy in the news

Blogs on Lassa fever medical therapy

Directions to Hospitals Treating Lassa fever

Risk calculators and risk factors for Lassa fever medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.; Ammu Susheela, M.D. [2]

Overview

Intravenous (IV) ribavirin is the antiviral drug of choice for the treatment of Lassa fever. Ribavirin is administered intravenously for a total of 10 days using the following regimen: first, loading dose of 30 mg/kg (max. 2g) followed by a dose of 16 mg/kg (max. 1g) IV q6h for 4 days, followed by a dose of 8 mg/kg (max. 500mg) IV q8h for 6 days. In addition to antiviral therapy, management includes supportive care to adequately maintain respiratory status, as well as fluid and electrolyte balance.

Medical Therapy

  • All hospitalized individuals with suspected Lassa fever should be isolated with proper disposal of body fluids and excreta.
  • Supportive care, including adequate fluid and electrolyte replacement and blood transfusions, may also be required.
  • Intravenous (IV) ribavirin is the antiviral drug of choice for the treatment of Lassa fever.
  • Ribavirin is more effective when administered early in the course of the disease than when administered late.[1]
  • Compared with oral ribavirin, intravenous (IV) ribavirin is almost twice as effective.[2]
Optimal Treatment
Ribavarin[3]
  • Loading dose: 30 mg/kg (max. 2g) IV
  • Concentration dose: 16 mg/kg (max. 1g) IV q6h for 4 days, then 8 mg/kg (max. 500mg) IV q8h for 6 days

Pregnancy

  • For 3rd-term pregnant women with Lassa fever, the risk of death is very high (odds ratio for death 5.57). Among these patients, emergent evacuation of the uterus (by induction or surgically) has been demonstrated to decrease the risk of death.[4] It is hypothesized that evacuating the uterus decreases the viral load significantly as the virus has high affinity for the placenta and other highly vascular tissues. Observational studies have demonstrated that the fetus has only a one in ten chance of survival irrespective of the therapies used or the interventions attempted. For that reason, the main focus is on reducing the risk of death in the mother. Following active obstetrical intervention, treatment with ribavirin should be initiated immediately.

References

  1. Fact sheet N°179: Lassa Fever. World Health Organization. Accessed on June 09, 2015.
  2. Fisher-Hoch SP, McCormick JB (2004). "Lassa fever vaccine". Expert review of vaccines. 3 (2): 189–97. doi:10.1586/14760584.3.4.S189. PMID 15056044.
  3. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB; et al. (2002). "Hemorrhagic fever viruses as biological weapons: medical and public health management". JAMA. 287 (18): 2391–405. PMID 11988060.
  4. Price ME, Fisher-Hoch SP, Craven RB, McCormick JB (1988). "A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy". BMJ. 297 (6648): 584–7. PMID 3139220.


Template:WikiDoc Sources